



Oncology Venture

## Pres Release

# Oncology Venture is streamlining its communications by publishing press releases in English only going forward.

**Hørsholm, November 12, 2019 – Oncology Venture A/S (“Oncology Venture”) today announces that the company has chosen to streamline its communications by publishing press releases in English only going forward.**

**For further information, please contact:**

Henrik Moltke, CFO  
E-mail: [hm@oncologyventure.com](mailto:hm@oncologyventure.com)  
Telephone +45 53 63 96 37

### About Oncology Venture A/S

Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, DRP®. The company has a mature portfolio of seven drug candidates, including compounds in the pre-registration stage.

The product portfolio includes: 2X-121 a PARP inhibitor in Phase 2 for Ovarian cancer; Dovitinib, for Renal Cell Carcinoma. Ixabepilone for the treatment of breast cancer. LiPlacis®, a liposomal formulation of cisplatin in Phase 2 trial for breast and prostate cancer 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; iriflufen, in Phase 2 for prostate cancer; and APO010, an immuno-oncology product in Phase 1/2 for multiple myeloma.

### About the Drug Response Predictor – DRP® Companion Diagnostic

Oncology Venture uses its multi gene DRP® to select those patients who by the genetic signature of their cancer are found to have a high likelihood of responding to the drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology. DRP® is based on messenger RNA from the patient's biopsies.

DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined.

The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs in the US.

### Follow us on social media:

Facebook: <https://www.facebook.com/oncologyventure/>  
LinkedIn: <https://www.linkedin.com/company/oncology-venture/>  
Twitter: <https://twitter.com/OncologyVenture>

Learn more at [oncologyventure.com](https://oncologyventure.com).

### Certified Adviser:

Svensk Kapitalmarknadsgranskning AB, Email: [ca@skmg.se](mailto:ca@skmg.se). Tel: +46 11 32 30 732

This information is information that Oncology Venture A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on November 12, 2019.